Will Riboxil be included in the medical insurance policy in 2025?

Ribociclib, also known as ribociclib, is a selective CDK4/6 inhibitor mainly used to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The drug has been officially approved for marketing in China and will be successfully included in the national medical insurance directory in 2024. The inclusion of medical insurance reimbursement has significantly reduced the treatment burden on patients, allowing more patients with advanced breast cancer to have access to targeted therapy and effectively extending progression-free survival.

In the domestic market, the common specifications of Riboxil are200mg×63 tablets pan>/ box, each box of the original drug was sold for about 8,000 to 9,000 yuan before medical insurance. After the inclusion of medical insurance, the price has been negotiated down to about 4,000 yuan, and the burden can be further reduced according to the reimbursement ratio of local medical insurance. The actual payment depends on the policy of the insured place, the reimbursement ratio and the patient's outpatient/ hospitalization status. Most patients only need to bear part of the out-of-pocket amount to take the medicine.

In overseas markets, Riboxiclib has also been on the market for many years. The price of the original drug in Europe is significantly higher than that in China. Common specifications such as 200mg×63 tablets/ are priced at more than 20,000 yuan per box. The price of the original research version produced in India is much lower, perhaps only more than 2,000 yuan per box, making it an alternative option for some self-paying patients. In addition, the generic drug of Riboxiclib produced by pharmaceutical companies such as Lucius in Laos has been launched. The drug ingredients are basically the same and the price is more affordable. The price of 200 mg × 21 tablets may be around more than 1,000 yuan, which is suitable for patients who are cost-sensitive but want to maintain treatment.

For Riboxil, which has been included in medical insurance, it is recommended that patients with medical insurance status give priority to purchasing it through regular hospital channels to obtain price discounts and medication protection. If medical insurance does not cover it or the area is not yet equipped with drugs, you can also choose legal and compliant international drug procurement channels to obtain original drugs or generic drugs. No matter which route is chosen, patients should strictly follow the oncologist's instructions when using Riboxil, and combine it with endocrine therapy and other combined programs to achieve maximum efficacy and reduce side effects.

Reference materials:https://us.kisqali.com/